Isryl-M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. This dual mechanism addresses both insulin deficiency and insulin resistance, providing effective glycemic control. Isryl-M 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise, for patients inadequately controlled on monotherapy or requiring combination therapy. The prolonged-release formulation ensures a steady plasma concentration, minimizing glycemic fluctuations and improving patient compliance. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Hypoglycemia risk is primarily associated with Glimepiride and necessitates careful dose titration and monitoring. Contraindications include severe renal or hepatic impairment, metabolic acidosis, and hypersensitivity to components. Regular monitoring of blood glucose, renal function, and lactic acid levels is recommended during therapy. Isryl-M 2 Tablet PR should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.

Dosage & How to Use